Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Revance Therapeutics
(NQ:
RVNC
)
3.020
-0.140 (-4.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Revance Therapeutics
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 20, 2021
Gainers Sesen Bio (NASDAQ:SESN) stock increased by 29.2% to $1.3 during Wednesday's regular session. Trading volume for this security as of 12:30 EST is 149.3 million...
Via
Benzinga
46 Biggest Movers From Yesterday
October 19, 2021
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...
Via
Benzinga
Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher
October 18, 2021
Toward the end of trading Monday, the Dow traded down 0.20% to 35,223.86 while the NASDAQ rose 0.68% to 14,998.54. The S&P also rose, gaining 0.19% to 4,480.05. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
August 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Earnings Scheduled For May 10, 2021
May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 18, 2021
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of...
Via
Benzinga
Revance Stock Loses 40% Of Its Value After FDA Rejects Its Frown Lines Injection
October 18, 2021
Revance Therapeutics tumbled Monday after the FDA rejected its frown lines injection.
Via
Investor's Business Daily
Exposures
Product Safety
Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet
October 18, 2021
Midway through trading Monday, the Dow traded down 0.05% to 35,275.96 while the NASDAQ rose 0.34% to 14,948.46. The S&P also rose, gaining 0.19% to 4,479.71. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
34 Stocks Moving In Monday's Mid-Day Session
October 18, 2021
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare....
Via
Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates
October 18, 2021
Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
October 18, 2021
The Nasdaq looks poised to open slightly lower after a strong week.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
10 Biggest Price Target Changes For Monday
October 18, 2021
Barclays reduced the price target for The Walt Disney Company (NYSE:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 18, 2021
Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion....
Via
Benzinga
Why Revance Therapeutics Stock Is Getting Crushed Today
October 18, 2021
A surprise rejection is weighing on the biopharma's shares today.
Via
The Motley Fool
21 Stocks Moving in Monday's Pre-Market Session
October 18, 2021
Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine...
Via
Benzinga
Exposures
COVID-19
Revance Shares Plunge On FDA Response Letter For Frown Line Candidate
October 18, 2021
The FDA has issued a Complete Response Letter (CRL) regarding Revance Therapeutics Inc's (NASDAQ: RVNC) marketing application for DaxibotulinumtoxinA for...
Via
Benzinga
Exposures
Product Safety
40 Stocks Moving In Wednesday's Mid-Day Session
October 13, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...
Via
Benzinga
50 Biggest Movers From Yesterday
October 14, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...
Via
Benzinga
Why Revance Therapeutics Stock Is Bolting Higher Today
October 13, 2021
Management's response to a publicly disclosed regulatory form has investors doing a U-turn.
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 13, 2021
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
October 13, 2021
MKM Partners raised the price target on Continental Resources, Inc. (NYSE:
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
October 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...
Via
Benzinga
Exposures
Product Safety
45 Biggest Movers From Yesterday
October 13, 2021
Gainers ESSTech Inc (NYSE: GWH) shares surged 128.4% to close at $23.80 onTuesday. ESS Inc, the Bill Gates-backed battery maker went public on the NewYork Stock Exchange on...
Via
Benzinga
How Bad Are Revance Therapeutics's Earnings? | Return On Capital Employed
September 03, 2021
Revance Therapeutics (NASDAQ:RVNC) brought in sales totaling $18.80 million during Q2 according to data provided by Benzinga Pro.However, earnings decreased 0.46%, resulting in a...
Via
Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Here is a look at some catalysts for the biopharam sector in the...
Via
Talk Markets
18 Key Biopharma Catalysts To Keep An Eye On In Q3
July 10, 2021
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne...
Via
Benzinga
Looking Into Revance Therapeutics's Return On Capital Employed
June 24, 2021
Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. Revance...
Via
Benzinga
Looking Into Revance Therapeutics's Return On Capital Employed
June 08, 2021
Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $13.30 million. Earnings fell to a loss of $70.01 million, resulting in a 10.21% decrease from last quarter. In Q4, Revance...
Via
Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
Recap: Revance Therapeutics Q1 Earnings
May 10, 2021
Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.